Profound Medical (PROF) news

Profound Medical and Telix Pharmaceuticals enter co-education agreement to advance PSMA-informed prostate care

Telix Pharmaceuticals has entered into a co-educational agreement with Profound Medical to advance the integration of PSMA-PET imaging into prostate cancer treatment workflows. The collaboration aims to explore how Telix’s PSMA-PET imaging agents, Gozellix and Illuccix, can support emerging…

Profound Medical Corp Q3 rev view $7.1 mln -- LSEG IBES data

Profound Medical Corp. (NASDAQ: PROF) reported preliminary third-quarter 2026 revenue of approximately $7.1 million, according to LSEG IBES data. This marks a notable performance for the company, which has faced significant financial challenges in recent years, including a net loss of $32.74…

Profound Medical Corp - Q3 gross margin expected to exceed 70%

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) reported its Q3 2025 financial results on November 13, 2025, revealing a gross margin of 74.3% for the quarter, surpassing the 70% threshold. This marked a significant improvement from the 63.1% gross margin recorded in the same period of the prior…

Profound Medical reports strong preliminary third quarter 2026 revenue

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has reported strong preliminary revenue for the third quarter of 2026, driven by continued momentum in its commercial operations and expanding market adoption of its MRI-guided therapies. The company noted that its second-quarter 2026 financial results…

Profound Medical further strengthens executive leadership team with appointment of Richard Fabian as president